| Gene | Score gda | Association Type | Type | Original DB | Sentence supporting the association | PMID | PMID Year | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|
|
0.600 | GeneticVariation | disease | BEFREE | BRAF alterations are key in certain low-grade gliomas and pediatric gliomas but rarely in high-grade gliomas in adults. | 28271343 | 2017 | ||||
|
0.600 | GeneticVariation | disease | BEFREE | The aim of our study is to investigate the potential use of BRAF mutations on prognosis of glioma patients. | 28534272 | 2018 | ||||
|
0.600 | GeneticVariation | disease | BEFREE | Therapeutic and Prognostic Implications of BRAF V600E in Pediatric Low-Grade Gliomas. | 28727518 | 2017 | ||||
|
0.600 | Biomarker | disease | BEFREE | The use of poly(adenosine 5'-diphosphate-ribose) inhibitors may be another way of specifically targeting IDH-mutant gliomas in addition to specific inhibitors, demethylating agents and anti-IDH vaccines. v-raf murine sarcoma viral oncogene homolog B1 (BRAF)-mutant anaplastic xanthoastrocytomas and gangliogliomas may benefit from BRAF and mitogen-activated protein kinase inhibitors. | 28901965 | 2017 | ||||
|
0.600 | Biomarker | disease | BEFREE | The work from Wang and colleagues identifies an acquired secondary BRAF mutation that confers resistance to pharmacologic BRAF inhibition in a BRAF<sup>V600E</sup> glioma. | 30181170 | 2018 | ||||
|
0.600 | GeneticVariation | disease | BEFREE | The case emphasizes the importance of comprehensive assessment based on pathological, genetic and clinical findings and calls for further investigations of non-diffuse glioma with H3F3A K27M and glioma with H3F3A K27M and BRAF V600E. | 31254135 | 2019 | ||||
|
0.600 | AlteredExpression | disease | BEFREE | TERT expression is susceptible to BRAF and ETS-factor inhibition in BRAF<sup>V600E</sup>/TERT promoter double-mutated glioma. | 31391125 | 2019 | ||||
|
0.600 | Biomarker | disease | BEFREE | We recommend that the neuro-oncologist consider using these drugs primarily in the setting of a clinical trial for patients with BRAF-altered glioma in order to advance our knowledge of their efficacy in this patient population. | 31466300 | 2019 | ||||
|
0.600 | GeneticVariation | disease | BEFREE | This may be useful in up to 3% of glioma patients with BRAF mutations. | 31748891 | 2020 |